8-K current report · filed Sep 3, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: September 3, 2026

Item 3.03TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 3.03 (Material Modification to Rights of Security Holders). ADS program termination expected at market open September 14, 2026.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.03 · Material Modification to Rights of Security Holders

  • ADS program termination expected at market open September 14, 2026
  • Mandatory exchange: each ADS converts into one NYSE-listed ordinary share
  • Rights structure shifts from ADS ownership to direct ordinary-share ownership
  • Amendment No. 1 updates the deposit agreement and ADR to facilitate the conversion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.